Graphic Health Warnings on Cigarette Packaging Delayed Until 2023

Nov.16.2022
Graphic Health Warnings on Cigarette Packaging Delayed Until 2023
Graphic health warnings for cigarettes delayed until November 2023, per a Texas court order.

It won't be until early November 2023 that cigarette packaging and advertisements will feature graphic health warnings.


The Eastern District Court of Texas in the United States has issued an order to further delay the effective date of the Food and Drug Administration's (FDA) graphic cigarette health warning regulation from October 6, 2023, to November 6, 2023, for an additional 31 days.


According to the National Association of Tobacco Outlets (NATO), a court order issued on November 7 has extended the deadline for manufacturers and retailers to submit their preferred rotation plans for cigarette health warning labels to the FDA by 31 days.


Every tobacco manufacturer and retailer who makes their own cigarette advertisements is required to submit a plan to the FDA that outlines a schedule for rotating the use of 11 graphic cigarette health warnings in their ads. The association stated that the preferred submission deadline for the cigarette health warning rotation plan is now January 6, 2023.


According to NATO, the court is expected to make a ruling on the motion for summary judgment in the case within 31 days.


In March 2020, the FDA released a final rule about warnings that includes text and image combinations that describe some of the health risks associated with smoking. However, implementation has been repeatedly delayed after several tobacco companies requested a specific date be set.


The Eastern District Court of Texas has postponed the deadline for the final time on August 20, setting the new deadline for October 6, 2023.


These warnings must appear on the top 50% of the front and back of cigarette packaging, as well as on at least 20% of the top of cigarette advertisements. Additionally, as previously reported by Convenience Store News, these warnings must be randomly and evenly displayed and distributed on cigarette packaging, and rotated quarterly in cigarette advertisements.


There are 11 essential warnings that need to be addressed. They include:


Warning: Tobacco smoke can harm your children. Warning: Tobacco smoke can cause deadly lung diseases in non-smokers. Warning: Smoking can lead to head and neck cancer. Warning: Smoking can cause bladder cancer, leading to blood in urine. Warning: Smoking during pregnancy can hinder fetal growth. Warning: Smoking can block arteries, leading to heart disease and stroke. Warning: Smoking can cause chronic obstructive pulmonary disease, a potentially fatal lung disease. Warning: Smoking can decrease blood flow and cause erectile dysfunction. Warning: Smoking can decrease blood flow to the limbs, possibly requiring amputation. Warning: Smoking can cause type 2 diabetes, raising blood sugar. Warning: Smoking can cause cataracts, leading to blindness.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13
 BAT London Shares Gain 13.99% as FDA Vape Decision Draws Market Attention
BAT London Shares Gain 13.99% as FDA Vape Decision Draws Market Attention
British American Tobacco’s London-listed shares rose 13.99% last week, as investors focused on the U.S. Food and Drug Administration’s recent authorization of flavored Glas e-cigarette products, the dismissal of a U.S. sanctions-related criminal case against BAT, and the company’s previously announced share buyback plan and newer nicotine business performance.
BAT
May.18
BAT New Zealand Says Illicit Tobacco Trade Drove Nearly 29% Revenue Decline in 2025
BAT New Zealand Says Illicit Tobacco Trade Drove Nearly 29% Revenue Decline in 2025
British American Tobacco New Zealand said the illicit tobacco trade is responsible for its profit halving and revenue falling between the 2024 and 2025 financial years. Financial results filed with the Companies Office show that BAT Holdings (New Zealand) recorded 2025 revenue of NZ$180.7 million, or about US$106.95 million based on the European Central Bank’s April 27, 2026 reference rates, down from NZ$254 million, or about US$150.33 million, in 2024.
Apr.28 by 2FIRSTS.ai
AP Questions FDA Rationale as Glas Fruit-Flavored Vapes Won Authorization Without Added Cessation Benefit
AP Questions FDA Rationale as Glas Fruit-Flavored Vapes Won Authorization Without Added Cessation Benefit
The U.S. Food and Drug Administration (FDA) recently authorized two fruit-flavored vaping products from Glas, but a newly released agency memo shows the products did not demonstrate greater smoking-cessation benefits than tobacco-flavored e-cigarettes. The Associated Press said the findings are likely to raise further questions about the FDA’s regulatory rationale and standards for flavored vaping products.
Jun.12
Special Report|U.S.-Facing Retailer Lists RELX Creator Pro 15K: A Chinese Brand Signal Under FDA’s Lower-Priority Enforcement Window
Special Report|U.S.-Facing Retailer Lists RELX Creator Pro 15K: A Chinese Brand Signal Under FDA’s Lower-Priority Enforcement Window
Vapesourcing has listed RELX Creator Pro 15K as “Coming Soon” with U.S. warehouse shipping options; while the page does not show that RELX has entered the U.S. market through official channels or that the product has received FDA authorization, the listing suggests that Chinese brand-led ENDS products are becoming a new point of observation as the U.S. market reassesses regulatory risk following the FDA’s updated enforcement-priority policy.
Industry Insight
Jun.11
UK Disposable Vape Ban Marks One Year as Adult Use Falls to 8% and Youth Use to 13%
UK Disposable Vape Ban Marks One Year as Adult Use Falls to 8% and Youth Use to 13%
One year after the UK ban on single-use disposable vapes took effect, YouGov data commissioned by Action on Smoking and Health shows that 13% of 11-17-year-old vapers and 8% of adult vapers now mainly use disposable products.
Jun.18